Shin Poong Pharmaceutical Co., Ltd. (019170) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Shin Poong Pharmaceutical Co., Ltd. (019170:KRX), powered by AI.

Current Price
₩7,210
P/E Ratio
41.9
Market Cap
377.9B
Sector
Healthcare
What is the Shin Poong Pharmaceutical Co., Ltd. stock price forecast?

Shin Poong Pharmaceutical Co., Ltd. is currently trading at ₩7,210. View real-time AI analysis on Alpha Lenz.

What is Shin Poong Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Shin Poong Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Shin Poong Pharmaceutical Co., Ltd.'s P/E ratio?

Shin Poong Pharmaceutical Co., Ltd.'s P/E ratio is 41.9.

Shin Poong Pharmaceutical Co., Ltd.

KRX · 019170
₩7,210-60(-0.83%)Market closedKRX regular session 09:00–15:30 KST
Ask about Shin Poong Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Shin Poong Pharmaceutical Co., Ltd. trades at a P/E of 41.9 (premium valuation) with modest ROE of 3.4%.

Ask for details

Company Overview

Shin Poong Pharmaceutical Co., Ltd. is a South Korean company engaged in the development, manufacturing, and distribution of pharmaceutical products. The company's primary function is to provide effective medical solutions and improve health care access through its diverse range of pharmaceuticals. Shin Poong focuses on the production of drugs across several therapeutic categories, including antibiotics, antivirals, and antimalarials, with notable contributions to combating infectious diseases like malaria. The company is renowned for its commitment to research and innovation, continuously investing in the development of novel treatments. In addition to its pharmaceutical endeavors, Shin Poong has an expanding portfolio in the biotechnology and health supplement sectors. Within the financial markets, Shin Poong Pharmaceutical holds significant influence due to its strategic initiatives in international markets and partnerships that extend its reach beyond South Korea. As one of the key players in the pharmaceutical industry, it plays a crucial role in advancing public health and addressing global medical challenges.

CEO유 제 만
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees809

Company Statistics

FY 2025

Profile

₩377,937,543,620Market Cap
₩234,680,653,220Revenue
52.42MShares Out
809Employees

Margins

43.75%Gross
10.83%EBITDA
6.07%Operating
3.60%Pre-Tax
3.57%Net

Valuation

41.92P/E
1.37P/B
1.58EV/Sales
14.92EV/EBITDA
27.89P/FCF

Growth (CAGR)

3.89%Rev 3Yr
3.48%Rev 5Yr
N/AOp Inc 3Yr
12.69%Op Inc 5Yr
N/ANet Inc 3Yr
10.70%Net Inc 5Yr

Returns

2.42%ROA
3.35%ROE
3.21%ROIC

Financial Health

₩47,432,744,880Cash & Cash Equivalents
₩34,305,940,270Net Debt
30.19%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Shin Poong Pharmaceutical Co., Ltd. (ticker: 019170) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 809 employees. Market cap is $377.9B.

The current price is ₩7,210 with a P/E ratio of 41.92x and P/B of 1.37x.

ROE is 3.35% and operating margin is 6.07%. Annual revenue is $234.7B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Shin Poong Pharmaceutical Co., Ltd. (019170) Stock Forecast 2026 ₩7,210 — Price, Financials & Analyst Targets | Alpha Lenz